SBIR/STTR Research Award

A NOVEL FAMILY OF LYMPHOCYTE ADHESION MOLECULES

Award identifier 02cfb3e2e837af525e88c7588ae6dbe26dfb4acab8d22d310e5b570a9459ccceAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$198,318

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ARBOR VITA CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
U5ASFV5Q36Y7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION: T cell activation is controlled by a highly organized multi-molecular structure at the T cell-antigen presenting cell interface. This structure has recently been termed an "immunological synapse." In an effort to find novel molecules involved in this synapse, they have identified a family of five previously uncloned cadherin-like lymphocyte transmembrane proteins (the CLASP family). At least one member of the family, murine CLASP-I, is localized at the immunological synapse. The goals of phase I of this research project are to clone and sequence at least three human genes of this family and to determine their tissue expression patterns and chromosomal localization. In addition, molecules that interfere with CLASP function, such as monoclonal antibodies or recombinant soluble CLASP proteins, will be synthesized and their effect on lymphocyte activation tested in vitro. In stage II of the project, the toxicity and efficacy of these potential therapeutics will be evaluated in animal models of organ transplantation and autoimmune disease and if positive results are obtained in clinical trials in humans. Together these studies should further their molecular understanding of the immunological synapse and yield commercially viable products that, by targeting this synapse, allow improved pharmacological regulation of the immune system. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

12 SBIR/STTR records share this UEI (2001–2013). Reported award amounts total $7,961,656. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.